AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 MAY 5 - (NewsRx.com & NewsRx.net) -- 6-Nitro-7-hdroxycoumarin may be a novel therapeutic agent for renal cell carcinoma.
"Previously, 7-hydroxycoumarin (7-OHC) and 6-nitro-7-hydroxycoumarin (6-NO2-7-OHC) have been shown to be potent and selective anti-proliferative agents to the human renal cell carcinoma (RCC) cell line, A-498. Their effect on mitogen-activated protein kinases (MAPK's) was investigated," wrote investigators in Ireland.
"6-NO2-7-OHC was shown to alter the phosphorylation status of ERK1/ERK2, p38 and SAPK, while 7-OHC activated ERK1/ERK2 but had no effect on p38 and SAPK Also, 7-OHC inhibited topoisomerase 11 mediated relaxation of DNA, while neither compound was a substrate for P-glycoprotein (P-gp) mediated multi-drug resistance (MDR)," scientists in Ireland report," reported G.J. Finn and colleagues.
"Therefore, 6-NO2-7-OHC, rather than 7-OHC, modulated signalling events associated with cellular differentiation and apoptosis, suggesting its mechanism of action may be the promotion of cellular maturation ...
Source: HighBeam Research, 6-Nitro-7-hdroxycoumarin novel therapeutic agent for renal cell...